Medically reviewed | Last updated: May 2026 | Reading time: approx. 12 min
| Key TakeawaysGLP-1 receptor agonists are not FDA-approved for Type 1 diabetes and are only used off-label under specialist supervision.Clinical trials suggest they may reduce HbA1c by 0.3% to 0.8%, body weight by 2.4 to 5 kg, and daily insulin requirements when added to insulin therapy.Risks include hypoglycemia, gastrointestinal side effects, and a theoretical concern around ketosis that warrants close monitoring. |
You may have heard about GLP-1 medications in the context of weight loss and Type 2 diabetes. What often gets left out of that conversation is whether people living with Type 1 diabetes can or should use them.
This article breaks down what the research shows, what the current regulatory stance is, and what anyone with Type 1 diabetes should understand before considering these medications.
1. First Things First: What Exactly Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are a class of medications that mimic a naturally occurring gut hormone called glucagon-like peptide-1. When you eat, your small intestine releases GLP-1, which triggers insulin secretion, suppresses glucagon, slows gastric emptying, and signals the brain to reduce appetite.
These drugs replicate that hormonal response in a sustained, pharmacological way.
The medications most commonly discussed include:
- Semaglutide (injectable: Ozempic; oral: Rybelsus) – once weekly injectable or once daily oral
- Liraglutide (Victoza) – once daily injectable
- Dulaglutide (Trulicity) – once weekly injectable
- Exenatide (Byetta; extended release: Bydureon) – twice daily or once weekly
- Tirzepatide (Mounjaro) – a dual GLP-1/GIP receptor agonist, once weekly injectable
In India, liraglutide (Victoza), dulaglutide (Trulicity), and semaglutide (Ozempic and Rybelsus) are currently available by prescription.
In March 2025, Eli Lilly launched tirzepatide (Mounjaro) in India as well. All of these are approved in India exclusively for Type 2 diabetes and weight management, not for Type 1 diabetes.
| Important NoteNone of these medications are approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency, or Indian regulatory authorities for the treatment of Type 1 diabetes. Any use in Type 1 diabetes is off-label and should only happen under the direct guidance of a specialist endocrinologist. |
2. Why Would Someone With Type 1 Diabetes Even Consider These Medications?
Type 1 diabetes is an autoimmune condition. The immune system destroys the insulin-producing beta cells in the pancreas, leaving the body entirely dependent on external insulin.
That distinction is critical and forms the foundation of every discussion about adjunct therapies.
Even with insulin therapy, achieving stable blood glucose control is genuinely difficult. Research published in Frontiers in Endocrinology (2025) found that only about 20% of people with Type 1 diabetes meet current glycemic targets.
Intensive insulin therapy also tends to promote weight gain, which compounds the challenge.
There are a few specific scenarios where clinicians have started exploring GLP-1 medications as an add-on to insulin. These include:
- People with Type 1 diabetes who also have overweight or obesity (BMI above 27 kg/m2)
- Individuals with persistently high HbA1c despite optimized insulin regimens
- People experiencing wide glucose variability or frequent post-meal spikes
- Those at elevated cardiometabolic risk who may benefit from the cardiovascular and renal protective effects observed in Type 2 diabetes trials
It is worth noting that obesity rates in people with Type 1 diabetes have risen considerably. The same 2025 Frontiers in Endocrinology review references NHANES 2021 to 2023 data showing that about 40.3% of U.S. adults have obesity, and comparable trends are being observed in people living with Type 1 diabetes globally.
3. What Does the Research Actually Show? The Evidence So Far
The evidence base for GLP-1 receptor agonists in Type 1 diabetes has grown considerably over the past few years, though it remains smaller than what exists for Type 2 diabetes.
The ADJUNCT ONE and ADJUNCT TWO Trials (Liraglutide)
Two large randomized controlled trials, ADJUNCT ONE (1,398 participants over 52 weeks) and ADJUNCT TWO (835 participants over 26 weeks), tested liraglutide 1.8 mg daily as an add-on to standard insulin therapy in people with Type 1 diabetes.
Results from both trials, reviewed in a 2024 effectiveness and safety analysis published in the Journal of Clinical Medicine, showed:
- HbA1c reductions of 0.33% to 0.54% compared to placebo
- Average body weight reduction of approximately 5 kg
- Lower total daily insulin requirements
However, the higher dose (1.8 mg) was associated with increased rates of hyperglycemia with ketosis, which is discussed in the safety section below.
Semaglutide in Type 1 Diabetes: Emerging Data
A Nature Medicine randomized crossover trial published in January 2025 evaluated semaglutide as an adjunct to automated insulin delivery in Type 1 diabetes. The primary endpoint was time in range (glucose between 3.9 and 10.0 mmol/L). The trial met its primary endpoint.
A real-world study from Dasman Diabetes Institute, published in 2024, followed adults with Type 1 diabetes and BMI above 27 kg/m2 receiving liraglutide, semaglutide, or tirzepatide for 12 months.
Published in PubMed Central (2025), the results found all three medications reduced body weight and improved metabolic markers without triggering severe hypoglycemia or DKA events in any group.
Meta-Analysis Data: What the Pooled Evidence Shows
A 2023 meta-analysis published in Frontiers in Pharmacology analyzed 11 randomized controlled trials of GLP-1 agonists as add-on therapy to insulin in Type 1 diabetes. Key pooled findings included:
| Outcome | Finding | Notes |
| HbA1c reduction | Modest but statistically significant | Effect size varies by drug and dose |
| Body weight | Meaningful reduction across studies | Average approximately 2-5 kg in 3-6 months |
| Total daily insulin dose | Significantly reduced | Consistent across different GLP-1 agents |
| DKA incidence | Not significantly increased vs. placebo | OR 1.38, 95% CI 0.93-2.05; not statistically significant |
| Hypoglycemia risk | Modestly increased | OR 1.89, 95% CI 1.06-3.39; statistically significant |
| GI adverse events | Higher vs. placebo | Nausea and vomiting most common |
Source: Tan et al., Frontiers in Pharmacology, 2023 | doi: 10.3389/fphar.2023.975880
A more recent 2025 systematic review and meta-analysis in Hormones looked at 25 randomized controlled trials and further confirmed improvements in HbA1c, body weight, and insulin dose reduction when GLP-1 agonists were added to insulin in Type 1 diabetes.
4. How GLP-1 Medications Work in the Type 1 Diabetes Context
In Type 2 diabetes, a large part of GLP-1 medications’ glucose-lowering effect comes from stimulating the remaining beta cells to secrete more insulin.
That mechanism is absent in Type 1 diabetes, because those cells have been destroyed.
The benefits observed in Type 1 diabetes appear to work through different pathways, which a 2024 mechanistic review published in the International Journal of Molecular Sciences outlines in detail:
- Glucagon suppression: People with Type 1 diabetes have dysregulated glucagon secretion from the alpha cells of the pancreas. GLP-1 agonists suppress glucagon, reducing hepatic glucose production and stabilizing post-meal blood sugar levels.
- Slower gastric emptying: By delaying how quickly food leaves the stomach, these medications blunt post-meal glucose spikes.
- Appetite suppression and weight reduction: Reduced caloric intake and weight loss can improve overall insulin sensitivity.
- Possible beta-cell preservation: In people with Type 1 diabetes who still have some residual insulin secretion (detectable C-peptide), GLP-1 agonists may offer modest beta-cell protective effects, though this area of research is still early.
This is why the glycemic benefits seen in Type 1 diabetes trials tend to be more modest than in Type 2 diabetes trials. The incretin-driven insulin secretion pathway is simply not available.
5. What Are the Real Safety Concerns?
This is where the conversation becomes more nuanced. The safety profile of GLP-1 agonists in Type 1 diabetes is not the same as in Type 2 diabetes, and both clinicians and patients need to understand where the additional risks lie.
Hypoglycemia
Because GLP-1 agonists reduce total daily insulin requirements, the dose of background and mealtime insulin typically needs to be adjusted downward after starting these medications. Failing to do that adjustment creates a real risk of low blood sugar.
The pooled meta-analysis by Tan et al. found a statistically significant increase in hypoglycemia risk (OR 1.89). That risk is primarily the result of not reducing insulin doses to match the new, lower requirements, rather than a direct hypoglycemic effect of the GLP-1 medication itself.
Ketosis and the Question of DKA
This is the most frequently cited safety concern. Diabetic ketoacidosis (DKA) is a life-threatening complication that occurs when insulin levels fall too low and the body switches to ketone production. There has been ongoing debate about whether GLP-1 agonists increase DKA risk in Type 1 diabetes.
The higher dose of liraglutide (1.8 mg) in the ADJUNCT trials was associated with increased rates of hyperglycemia with ketosis, though this did not translate to a statistically significant increase in DKA events in pooled meta-analysis data.
A recent real-world study presented at the American Association of Clinical Endocrinology Annual Conference in April 2026 found no hospital admissions for DKA or pancreatitis over one year among adults with Type 1 diabetes using a GLP-1 receptor agonist.
Overall hospital admission rates were actually lower for GLP-1 users compared with non-users. However, this is a single-center study and should be interpreted cautiously until larger controlled data confirm it.
The important practical takeaway: GLP-1 agonists do not carry the same elevated DKA risk as SGLT-2 inhibitors (which were withdrawn from Type 1 diabetes use in Europe specifically because of DKA risk).
But ketone monitoring is still recommended, particularly when GI side effects cause reduced food intake or when insulin doses are being titrated down.
Gastrointestinal Side Effects
Nausea, vomiting, and reduced appetite are common, particularly in the early weeks of treatment. For people with Type 1 diabetes, severe vomiting carries a specific concern: when someone is not eating but still has their usual insulin dose on board, blood sugar can drop rapidly.
Anyone using these medications needs a clear protocol from their care team for managing sick days.
| Safety Summary for Type 1 Diabetes UseAdjust insulin doses proactively as weight decreases and insulin sensitivity improvesMonitor blood ketone levels regularly, especially during illness or reduced food intakeHave a clear sick-day protocol in place with your endocrinologist before startingReport persistent nausea, vomiting, or abdominal pain to your care team immediatelyCarry fast-acting glucose at all times given the modestly increased hypoglycemia risk |
6. What Is the Current Regulatory Status Globally and in India?
GLP-1 receptor agonists have no approved indication for Type 1 diabetes anywhere in the world as of May 2026.
| Region / Agency | Current Status for Type 1 Diabetes | Notes |
| U.S. FDA | Not approved | Off-label use only, under specialist care |
| European Medicines Agency | Not approved | Previous limited EU approvals for liraglutide in T1D were withdrawn |
| CDSCO (India) | Not approved | All GLP-1 approvals in India are for T2D and obesity only |
| Health Canada | Not approved | Same position as FDA |
One important historical note: liraglutide briefly received conditional approval in some European markets as an adjunct therapy for Type 1 diabetes, but this was ultimately withdrawn due to safety concerns and commercial reasons.
This history shapes how regulators currently approach this question.
What makes this regulatory picture particularly important for Indian readers: the GLP-1 market in India is growing rapidly, with tirzepatide (Mounjaro) launched in March 2025 and Wegovy (semaglutide for obesity) expected by 2026.
Wider availability does not mean these medications become appropriate for Type 1 diabetes use without specialist oversight.
7. Off-Label Use: What Does “Off-Label” Actually Mean in Practice?
Off-label prescribing refers to a physician prescribing a medication for a condition, population, or dose that falls outside the approved label, based on clinical judgment and available evidence.
Off-label prescribing is legal, common, and often appropriate. It happens across medicine in situations where the evidence supports a use that regulators have not formally approved.
In the United States, a 2024 JAMA study reviewed data from 943,456 people with Type 1 diabetes (2010 to 2023) via the Epic Cosmos database and found that off-label use of GLP-1 receptor agonists in Type 1 diabetes has been increasing, primarily driven by the need to address obesity, cardiovascular risk, and renal complications in this population.
As of 2025, estimates suggest that approximately 30% of people with Type 1 diabetes in the U.S. are now using GLP-1 receptor agonists, according to data presented at the American Diabetes Association Annual Meeting.
What responsible off-label use looks like:
- Initiated by an endocrinologist with experience in complex Type 1 diabetes management, not a general practitioner
- Accompanied by a documented discussion of known benefits, known risks, and areas where evidence is still insufficient
- Supported by close monitoring: HbA1c, weight, insulin dose adjustment, and ketone levels
- Part of a broader plan that includes continuous glucose monitoring and, ideally, automated insulin delivery
8. GLP-1 Agonists and Automated Insulin Delivery: A Promising Combination?
One area generating particular research interest is combining GLP-1 agonists with automated insulin delivery (AID) systems, sometimes called closed-loop systems.
These devices use a continuous glucose monitor, an algorithm, and an insulin pump to adjust insulin delivery automatically throughout the day.
The 2025 Nature Medicine crossover trial specifically tested semaglutide as an adjunct to an automated insulin delivery system.
It met its primary endpoint of improved time in range, and individuals with the greatest weight reduction showed the most glycemic benefit.
The practical implication: AID systems can partially compensate for the rapid changes in insulin sensitivity that accompany weight loss from GLP-1 therapy, potentially making this combination more manageable than GLP-1 added to conventional multiple daily injection regimens.
Clinicians using this approach should expect to adjust insulin pump settings more frequently as weight decreases. Some individuals may see insulin dose reductions of up to 50%, according to expert commentary presented at the ADA Meeting.
| Bottom LineGLP-1 receptor agonists are not approved for Type 1 diabetes and cannot replace insulin therapy, which remains the cornerstone of Type 1 diabetes management. However, the emerging evidence suggests they may offer meaningful benefits as an adjunct therapy for select individuals with Type 1 diabetes, particularly those with obesity or suboptimal glycemic control. Given the real risks of hypoglycemia, ketosis, and gastrointestinal complications, any decision to use these medications should be made carefully with a specialist endocrinologist and accompanied by close clinical monitoring. |
Frequently Asked Questions
Can GLP-1 medications be used for Type 1 diabetes?
GLP-1 receptor agonists are not approved for Type 1 diabetes by the FDA, EMA, or Indian drug regulators. However, they are increasingly used off-label under specialist supervision in people with Type 1 diabetes who also have obesity or inadequate glycemic control. Any use should be guided by an endocrinologist with experience in Type 1 diabetes management.
Are GLP-1 agonists approved for Type 1 diabetes treatment?
No. As of May 2026, no regulatory authority in the world has approved a GLP-1 receptor agonist specifically for Type 1 diabetes. The FDA, EMA, and CDSCO (India) all currently restrict approval of these medications to Type 2 diabetes and obesity indications. Use in Type 1 diabetes remains off-label.
Do GLP-1 medications cause diabetic ketoacidosis in Type 1 diabetes?
Pooled meta-analysis data from randomized trials has not found a statistically significant increase in DKA risk with GLP-1 agonists in Type 1 diabetes. However, higher doses of liraglutide were associated with elevated ketosis rates in ADJUNCT trials, and close monitoring of blood ketones remains an important precaution. Unlike SGLT-2 inhibitors, which carry a clear DKA risk in Type 1 diabetes, GLP-1 agents appear to carry a more modest and manageable risk profile.
Can a person with Type 1 diabetes take Ozempic or Wegovy?
Semaglutide (Ozempic for diabetes, Wegovy for obesity) is not approved for Type 1 diabetes. Some endocrinologists do prescribe it off-label for carefully selected patients with Type 1 diabetes and significant overweight. This should never be self-initiated. Anyone with Type 1 diabetes interested in these medications should raise the question directly with their specialist, not self-prescribe based on information from news articles or social media.
Will insulin still be needed if someone with Type 1 diabetes uses GLP-1 medications?
Yes, always. People with Type 1 diabetes have little or no insulin-producing beta cell function remaining. GLP-1 agonists work through different mechanisms and cannot substitute for insulin. In studies, GLP-1 add-on therapy reduces the total daily insulin dose needed but does not eliminate the need for insulin entirely. Stopping insulin while on a GLP-1 medication would be dangerous.
| Medical DisclaimerThis article is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. GLP-1 receptor agonists are not approved for Type 1 diabetes. Any person living with Type 1 diabetes who is interested in these medications should consult a qualified endocrinologist before making any changes to their treatment regimen. Never adjust insulin doses or start new medications without guidance from your healthcare provider. |
